{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:38:43Z","timestamp":1788385123108,"version":"build-2803163510"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hodgkin lymphoma (HL) in older patients, commonly defined as \u226560 years of age, is a disease for which survival rates have historically been significantly lower compared with younger patients. Older HL patients appear to have different disease biology compared with younger patients, including increased incidence of mixed cellularity histology, Epstein-Barr virus\u2013related, and advanced-stage disease. For prognostication, several studies have documented the significance of comorbidities and functional status in older HL patients, as well as the importance of achieving initial complete remission. Collectively, selection of therapy for older HL patients should be based in part on functional status, including pretreatment assessment of activities of daily living (ADL), comorbidities, and other geriatric measures (eg, cognition, social support). Treatment of fit older HL patients should be given with curative intent, regardless of disease stage. However, attention should be paid to serious treatment-related toxicities, including risk of treatment-related mortality. Although inclusion of anthracycline therapy is important, bleomycin-containing regimens (eg, doxorubicin, bleomycin, vinblastine, dacarbazine) may lead to prohibitive pulmonary toxicity, and intensive therapies (eg, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are too toxic. Brentuximab vedotin given sequentially before and after doxorubicin, vinblastine, and dacarbazine to fit, untreated advanced-stage older HL patients was recently shown to be tolerable and highly effective. Therapy for patients who are unfit or frail because of comorbidities and\/or ADL loss is less clear and should be individualized with consideration of lower-intensity therapy, such as brentuximab vedotin with or without dacarbazine. Altogether, therapy for older HL patients should be tailored based upon a geriatric assessment, and novel targeted agents should continue to be integrated into treatment paradigms.<\/jats:p>","DOI":"10.1182\/hematology.2019000028","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:12:05Z","timestamp":1575645125000},"page":"233-242","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Management of older Hodgkin lymphoma patients"],"prefix":"10.1182","volume":"2019","author":[{"given":"Andrew M.","family":"Evens","sequence":"first","affiliation":[{"name":"Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Carter","sequence":"additional","affiliation":[{"name":"Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[{"name":"Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019120610095378500_B1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Treatment outcome in Hodgkin\u2019s disease in patients above the age of 60: a population-based study","volume":"2","author":"Enblad","year":"1991","journal-title":"Ann Oncol"},{"issue":"22","key":"2019120610095378500_B2","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019120610095378500_B3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO;2-X","article-title":"Hodgkin disease in the elderly. A registry-based analysis","volume":"70","author":"Erdkamp","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"2019120610095378500_B4","first-page":"1087","article-title":"Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7-8","key":"2019120610095378500_B5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/028418602321028283","article-title":"Patients above sixty years of age with Hodgkin\u2019s lymphoma treated with a new strategy","volume":"41","author":"Enblad","year":"2002","journal-title":"Acta Oncol"},{"issue":"12","key":"2019120610095378500_B6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019120610095378500_B7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin\u2019s disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2019120610095378500_B8","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/1097-0142(19930301)71:5<1857::AID-CNCR2820710524>3.0.CO;2-B","article-title":"Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B","volume":"71","author":"Mir","year":"1993","journal-title":"Cancer"},{"issue":"3","key":"2019120610095378500_B9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0959-8049(99)00267-1","article-title":"Long-term survival in Hodgkin\u2019s disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries","volume":"36","author":"Roy","year":"2000","journal-title":"Eur J Cancer"},{"issue":"1","key":"2019120610095378500_B10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2019120610095378500_B11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.13090","article-title":"Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma - a population-based study from Sweden","volume":"101","author":"Bj\u00f6rkholm","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"2019120610095378500_B12","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"issue":"25","key":"2019120610095378500_B13","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019120610095378500_B14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"2019120610095378500_B15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019120610095378500_B16","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019120610095378500_B17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry","volume":"41","author":"van Spronsen","year":"2005","journal-title":"Eur J Cancer"},{"issue":"6","key":"2019120610095378500_B18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","article-title":"The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression","volume":"128","author":"Kelley","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2019120610095378500_B19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/10428190290033332","article-title":"Treatment of elderly Hodgkin\u2019s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study","volume":"43","author":"Macpherson","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2019120610095378500_B20","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019120610095378500_B21","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"issue":"20","key":"2019120610095378500_B22","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood-2017-05-736975","article-title":"Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019120610095378500_B23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"issue":"7","key":"2019120610095378500_B24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002770050521","article-title":"Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma, 1993-1996","volume":"78","author":"van Spronsen","year":"1999","journal-title":"Ann Hematol"},{"issue":"2","key":"2019120610095378500_B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/10428194.2018.1482539","article-title":"Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group","volume":"60","author":"Wrobel","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"30","key":"2019120610095378500_B26","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019120610095378500_B27","first-page":"450","article-title":"Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin\u2019s disease patients","volume":"81","author":"Levis","year":"1996","journal-title":"Haematologica"},{"issue":"2","key":"2019120610095378500_B28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0360-3016(02)04596-0","article-title":"Hodgkin\u2019s disease in elderly patients (&gt; or =60): clinical outcome and treatment strategies","volume":"56","author":"Kim","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2019120610095378500_B29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.1989.tb00268.x","article-title":"Hodgkin\u2019s disease and age","volume":"43","author":"Specht","year":"1989","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019120610095378500_B30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"2019120610095378500_B31","first-page":"46","article-title":"Probability of cure in elderly Hodgkin\u2019s disease patients","volume":"79","author":"Levis","year":"1994","journal-title":"Haematologica"},{"issue":"18","key":"2019120610095378500_B32","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019120610095378500_B33","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019120610095378500_B34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"2019120610095378500_B35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","article-title":"Bleomycin lung toxicity: who are the patients with increased risk?","volume":"18","author":"Azambuja","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"issue":"30","key":"2019120610095378500_B36","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019120610095378500_B37","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019120610095378500_B38","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged &gt;\/=60 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2019120610095378500_B39","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019120610095378500_B40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/annonc\/mdl379","article-title":"Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin\u2019s lymphoma: an analysis from the German Hodgkin Study Group","volume":"18","author":"Klimm","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"2019120610095378500_B41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019120610095378500_B42","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/annonc\/mdl094","article-title":"A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients","volume":"17","author":"Landgren","year":"2006","journal-title":"Ann Oncol"},{"issue":"6","key":"2019120610095378500_B43","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2019120610095378500_B44","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019120610095378500_B45","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"Halbsguth","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019120610095378500_B46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-101-4-447","article-title":"BCVPP chemotherapy for advanced Hodgkin\u2019s disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study","volume":"101","author":"Bakemeier","year":"1984","journal-title":"Ann Intern Med"},{"issue":"24","key":"2019120610095378500_B47","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019120610095378500_B48","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2019120610095378500_B49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjh.15741","article-title":"Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial","volume":"185","author":"B\u00f6ll","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2019120610095378500_B50","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2018-99-119363","article-title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)","volume":"132","author":"Boell","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120610095378500_B51","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2018-99-112178","article-title":"Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): a detailed analysis from the Phase 3 ECHELON-1 Study","volume":"132","author":"Evens","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019120610095378500_B52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF02897235","article-title":"An effective oral combination in advanced relapsed Hodgkin\u2019s disease prednisolone, etoposide, chlorambucil and CCNU","volume":"26","author":"Lennard","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2019120610095378500_B53","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/bmt.2010.294","article-title":"High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin\u2019s lymphoma","volume":"46","author":"Puig","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"35","key":"2019120610095378500_B54","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019120610095378500_B55"},{"issue":"4","key":"2019120610095378500_B56","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"2019120610095378500_B57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0277-9536(91)90150-B","article-title":"The MOS social support survey","volume":"32","author":"Sherbourne","year":"1991","journal-title":"Soc Sci Med"},{"key":"2019120610095378500_B58"},{"key":"2019120610095378500_B59"},{"key":"2019120610095378500_B60"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/233\/1546207\/hem2019000028c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/233\/1546207\/hem2019000028c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:43:07Z","timestamp":1695494587000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/233\/422626\/Management-of-older-Hodgkin-lymphoma-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000028","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}